<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583657</url>
  </required_header>
  <id_info>
    <org_study_id>Oil4Egg</org_study_id>
    <nct_id>NCT04583657</nct_id>
  </id_info>
  <brief_title>Intestinal Tolerance &amp; Health Effects of Daily Consumption of Two Eggs With Fatty Acid Profile Related to Metabolic Disorders</brief_title>
  <acronym>Oil4Egg</acronym>
  <official_title>To Evaluate the Intestinal Tolerance and Health Effects of Daily Consumption of Two Eggs With a Particular Fatty Acid Profile on a Set of Parameters Related to Metabolic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has two objectives: 1) to check that the daily consumption of two eggs with a&#xD;
      particular fatty acid pattern rich in n-3 polyunsaturated fatty acids (α-linolenic acid,&#xD;
      docosahexaenoic acid), conjugated-linoleic acid and conjugated-linolenic acid is well&#xD;
      tolerated by the consumer ; 2) to evaluate the effects of the consumption of these eggs on&#xD;
      health parameters in subjects presenting a risk of developing a metabolic disorder.&#xD;
&#xD;
      This monocentric study is an interventional, randomized, double-blind, control study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids&#xD;
      show interesting effects in the context of health. Indeed, some studies suggest positive&#xD;
      effects on circulating lipids or inflammation associated with certain disorders such as&#xD;
      diabetes, following the consumption of these fatty acids.&#xD;
&#xD;
      However, these fatty acids are not very present in the classic diet. Therefore, we have&#xD;
      developped hens eggs naturally enriched in n-3 polyunsaturated fatty acids,&#xD;
      conjugated-linoleic acids and conjugated-linolenic acids by changing the hens feed.&#xD;
&#xD;
      This study has two objectives: 1) to check that the daily consumption of two eggs with a&#xD;
      particular fatty acid pattern rich in n-3 polyunsaturated fatty acids (α-linolenic acid,&#xD;
      docosahexaenoic acid), conjugated-linoleic acid and conjugated-linolenic acid is well&#xD;
      tolerated by the consumer ; 2) to evaluate the effects of the consumption of these eggs on&#xD;
      health parameters in subjects presenting a risk of developing a metabolic disorder.&#xD;
&#xD;
      To do this, 80 subjects aged 35 to 75, sedentary (&lt;2 hours of physical activity per week) and&#xD;
      with abdominal obesity (&gt; 94cm for men and&gt; 80cm for women) were recruited and were divided&#xD;
      into two groups: the control group (12 subjects consuming 2 classic eggs for 3 months per&#xD;
      day) or the test group (12 subjects consuming 2 eggs enriched in omega per day for 3 months).&#xD;
&#xD;
      A medical examination with blood sampling was scheduled every month at baseline (Day 0),&#xD;
      after one month (Day 30), after two months (Day 60) and at the end of the 3 months of&#xD;
      intervention (Day90). During those visits, the following were monitored: glucose parameters,&#xD;
      lipids parameters, fatty acid profile of red blood cells and plasma and safety parameters&#xD;
      related to haematology, kidney and liver functions .&#xD;
&#xD;
      During these monthly medical visits patients also completed the questionnaires assessing&#xD;
      intestinal tolerance (visual analogue scale showing 10 gastrointestinal symptoms), satiety&#xD;
      (visual analog scale questionnaire) and well-being (36 items short form survey). Eating&#xD;
      habits were monitored using a food diary. Additional parameters were measured only during the&#xD;
      first and the last visit: coagulation, nutritional status, endothelial function and&#xD;
      inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">April 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This monocentric study is an interventional, randomized, double-blind, controlled study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycated haemoglobin (HbA1c)</measure>
    <time_frame>Change from baseline (visit 1) glycated haemoglobin at 3 months (Day 90, visit 4)</time_frame>
    <description>Glycated haemoglobin (HbA1c) in blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic model assessment (HOMA)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative insulin sensitivity check index (QUICKI)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low-density lipoprotein (LDL) cholesterol</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-density lipoprotein (HDL) cholesterol</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-high-density lipoprotein cholesterol (non-HDL)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acid pattern in red blood cells</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acid pattern plasma</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urea</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium (Na)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium (K)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chlore (Cl)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphate (P)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase (ALAT)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase (ASAT)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyl transferase (GGT)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase (ALP)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipase</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume (MCV)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin concentration (MCHC)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cells</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cells</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood cell count</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocytes</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematocrit</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>Impedancemeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>Measuring tape</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>Measuring tape</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>Impedancemeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean mass</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>Impedancemeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral fat mass</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>Impedancemeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International normalized ratio (INR)</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated clotting time (ACT)</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% transferrin saturation</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin B12</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-hydroxy-vitamin D</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1b</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor alpha (TNFa)</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidized low-density lipoprotein (LDLox)</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrosylated hemoglobin (HbNO)</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>visual analog scale questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal tolerance</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>visual analog scale questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life 36-item short-form survey (SF36)</measure>
    <time_frame>baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)</time_frame>
    <description>SF36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive hyperemia index (LnRHI)</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>Tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation index normalized for heart rate (AI@75bpm)</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>Tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>Tensiometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>baseline (visit 1) and Day 90 (last visit 4)</time_frame>
    <description>Tensiometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated haemoglobin (HbA1c)</measure>
    <time_frame>Day 30 (visit 2) and Day 60 (visit 3)</time_frame>
    <description>Glycated haemoglobin in blood sample</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <condition>Abdominal Obesity</condition>
  <condition>Sedentary Behavior</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Consumption of two &quot;classical eggs&quot; per day during three months. The fatty acid pattern of those eggs is characterized by: total saturated fatty acid 34.25%, total monounsaturated fatty acid 47.68%, total n-6 polyunsaturated fatty acid 16.97%, total n-3 polyunsaturated fatty acid 1.10%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption of two test eggs per day during three months. These eggs are naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids (total saturated fatty acid 31.74%, total monounsaturated fatty acid 28.09%, total n-6 polyunsaturated fatty acid 16.07%, total n-3 polyunsaturated fatty acid 6.51%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Eggs</intervention_name>
    <description>Consumption of two eggs (control or test) per day during three months</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman or man, aged of 35 to 75 years&#xD;
&#xD;
          -  Abdominal obesity : waist circumference for men &gt; 94cm and &gt; 80cm for women&#xD;
&#xD;
          -  Practicing &lt; 2h of physical activity per week&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled systolic blood pressure &gt; 160/100mmHg&#xD;
&#xD;
          -  For premenopausal women: pregnant or lactating women&#xD;
&#xD;
          -  For menopausal women: less than 6 months of menopause&#xD;
&#xD;
          -  Perimenopausal women with symptoms&#xD;
&#xD;
          -  Type II diabetes (fasted glycaemia ≥ 126mg/dl or HbA1c ≥ 6.5%), Type I diabetes&#xD;
&#xD;
          -  Medical history or actual cardiovascular disease (myocardial infarction, angina,&#xD;
             transient ischemic attack, lower limb arteriopathy)&#xD;
&#xD;
          -  Familial history of premature cardiovascular incident (in male first degree relative &lt;&#xD;
             55 years and in female first degree relative &lt; 65 years; myocardial infarction,&#xD;
             angina, transient ischemic attack, lower limb arteriopathy)&#xD;
&#xD;
          -  Medical history or actual liver, pancreas, kidney, pulmonary or gastrointestinal&#xD;
             problem&#xD;
&#xD;
          -  Thyroid disorder&#xD;
&#xD;
          -  Cancer &lt; 5 years before the screening visit&#xD;
&#xD;
          -  Smokers or who have stopped smoking within 6 months before the screening visit&#xD;
&#xD;
          -  Subject presenting allergy or food intolerance to eggs&#xD;
&#xD;
          -  Subjects with psychiatric problems and/or using antipsychotics&#xD;
&#xD;
          -  Drug addiction problem&#xD;
&#xD;
          -  Recent change of body weight &gt; 5kg (&lt; 3 months before the screening visit)&#xD;
&#xD;
          -  Within 3 months before the screening visit, change in the chronic (&gt; 7 days in a row)&#xD;
             intake or dosage of drug(s) or product(s) modifying&#xD;
&#xD;
               -  The glucose or lipid metabolism&#xD;
&#xD;
               -  The blood pressure and heart rate&#xD;
&#xD;
               -  Intestinal tolerance&#xD;
&#xD;
               -  Hepatic, pancreas or kidney functions&#xD;
&#xD;
               -  Satiety&#xD;
&#xD;
               -  The inflammatory status&#xD;
&#xD;
          -  Current or recent (&lt; 3 months before the screening visit) intake of dietary&#xD;
             supplements rich in n-3 polyunsaturated fatty acid&#xD;
&#xD;
          -  Vegan diet&#xD;
&#xD;
          -  Consumption of fish &gt; 3 times per week&#xD;
&#xD;
          -  Subjects who drink more than 3 glasses of alcohol per day (&gt; 30 g of alcohol per day)&#xD;
&#xD;
          -  LDL &gt; 159 mg/dl or total cholesterol &gt; 239 mg/dl or triglyceride &gt; 200 mg/dl or HDL &lt;&#xD;
             40 mg/dl&#xD;
&#xD;
          -  Docosahexaenoic acid in red blood cell phospholipids &gt; 8 %&#xD;
&#xD;
          -  Subjects having participated to another clinical trial &lt; 1 month before the screening&#xD;
             test visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvan Larondelle, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Université Catholique de Louvain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center of Investigation in Clinical Nutrition</name>
      <address>
        <city>Louvain-La-Neuve</city>
        <zip>1348</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

